Blog - etira

Breakthroughs that
make news.

See news releases about Etira, our stellar team,
our breakthrough innovations and our relentless steps to improve the survival of patients with advanced cancers.

Drs. Jenkins and Stebbing join Etira Board

Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath, MD, PhD to…

Validation of ERX-208 in Ovarian Cancer

Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th Biennial Ovarian Cancer Research Symposium. The data establishes that ER stress in ovarian cancer (OCa) is targetable and the clinical utility of ERX-208.

ERX-315-001 SITE INITIATION VISIT @TKCC

Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…

ERX-315 CLINICAL TRIAL APPROVED BY HREC

Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…

Etira’s Australian partner MMIC expands

Melbourne, Australia - July 10, 2024: The expansion of Etira partner Medicines Manufacturing Innovation Centre (MMIC) to the Monash Technology Precinct in Clayton was highlighted in the press. This expansion will enable further opportunities…

DECRYPTING THE OLIGO-BENZAMIDE PLATFORM

Dallas, TX – June 15, 2024: The laboratory of Etira founder Dr Jung-Mo Ahn presents a comprehensive overview of the oligo-benzamide platform that emulates a-helical peptide segments in proteins and disrupts protein-protein interactions. Herein,…